The new Hollywood VI NanoMetalene transforaminal lumbar interbody fusion device has been commercially launched by SeaSpine Holdings Corporation, a Carlsbad, CA-based medical technology company focused on surgical solutions for the treatment of spinal disorders.
The device, which has been successfully implanted, is indicated for use in spinal fusion procedures at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD).
It is the most recent device to leverage SeaSpine’s exclusive rights to the NanoMetalene technology within the spine market. This implant adds to the NanoMetalene family of products, which already includes the Hollywood NanoMetalene, Ventura NanoMetalene and cervical Cambria NanoMetalene interbody devices.
NanoMetalene is a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK-OPTIMA polymer from INVIBIO. It is applied in a proprietary high-energy, low-temperature surface process, which is different than other coating applications and allows for titanium nano topography to encompass the entire implant.
The NanoMetalene coating provides the surface benefits of titanium while retaining the benefits associated with traditional PEEK-OPTIMA devices such as biocompatibility, modulus of elasticity similar to bone, and excellent radiographic visibility for post-op imaging.
Keith Valentine, CEO of SeaSpine, said the company plans to continue to expand its NanoMetalene offering throughout 2016 and into 2017 to ensure the technology is available for all interbody spine procedures.
With a curved, anatomically geometric shape, the Hollywood VI NanoMetalene implant is suited for placement in the anterior column of the spine. The variable insertion (VI) design facilitates final implant placement within the disc space and provides TLIF surgeons options tailored for their patients. The device also features a completely coated graft aperture for autogenous bone graft for fusion.
